Radiopharm Theranostics Advances 177Lu-RAD202 Trial to Higher Dose Level
Event summary
- Radiopharm Theranostics advances 177Lu-RAD202 to 130mCi dose in Phase 1 'HEAT' trial after DSMC recommendation.
- Trial targets HER2-positive advanced solid tumors, with Cohort 3 escalation approved.
- Previous dose level (75mCi) announced on October 1, 2025; trial ongoing at Australian clinical centers.
- Company expects to complete Phase 1 dose escalation by the end of 2026.
The big picture
Radiopharm Theranostics' progress in the 177Lu-RAD202 trial reflects the growing focus on radiopharmaceuticals for precision oncology. The HER2-targeted approach aligns with broader trends in targeted cancer therapies, where radioligand therapeutics are gaining traction. The company's ability to rapidly advance dose levels could position it as a key player in the radiopharmaceutical space, though competition remains intense.
What we're watching
- Trial Execution
- Whether the accelerated dose escalation maintains safety and efficacy signals.
- Regulatory Pathway
- The pace at which Phase 1 completion could enable Phase 2 initiation.
- Competitive Positioning
- How RAD202 differentiates against existing HER2-targeted therapies.
Related topics